Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
The application of immunotherapy in the treatment of hematological malignancies is relatively new. Donor lymphocyte infusion (DLI) is a form of adaptive cellular therapy where the transfer of cells from immunocompetent donor to patient with cancer who relapsed after bone marrow transplantation results in destruction of the malignant cells. Hereby, we review the concepts, mechanisms, and results of the application of DLI in treatment of some hematological malignancies.
Owaidah
Tarek M
TM
Department of Pathology and Laboratory Medicine, MBC 10, King Faisal Specialist Hospital & Research Centre, PO Box 3354, Riyadh 11211, Kingdom of Saudi Arabia. towaidah@kfshrc.edu.sa
D016026:Bone Marrow Transplantation; D006086:Graft vs Host Disease / Q000276:immunology; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery / Q000628:therapy; D017710:Lymphocyte Transfusion; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome